GBT - Global Blood Therapeutics Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Global Blood Therapeutics Inc.

400 East Jamie Court
Suite 101
South San Francisco, CA 94080
United States

Full Time Employees95

Key Executives

Dr. Ted W. LoveChief Exec. Officer, Pres and Director711.88kN/A58
Dr. Charles J. Homcy M.D.Founder, Advisor and Director41.29kN/A69
Mr. Jeffrey S. FarrowChief Financial Officer416.22kN/A55
Ms. Tricia Borga Suvari Esq.Chief Legal Officer and Sec.82.16kN/A56
Dr. David R. Phillips Ph.D.Founder and AdvisorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Corporate Governance

Global Blood Therapeutics Inc.’s ISS Governance QualityScore as of February 1, 2018 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.